Bio-Gene Technology Ltd (ASX: BGT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Bio-Gene Technology Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Bio-Gene Technology Ltd (ASX: BGT)
Latest News
Small Cap Shares
Guess which ASX small-cap stock exploded 154% on big US news!
BGT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Bio-Gene Technology Ltd
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
BGT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Jan 2026 | $0.03 | $0.01 | 34.48% | 96,141 | $0.03 | $0.03 | $0.03 |
| 21 Jan 2026 | $0.03 | $0.00 | 0.00% | 109,184 | $0.03 | $0.03 | $0.03 |
| 19 Jan 2026 | $0.03 | $0.00 | 0.00% | 925,312 | $0.03 | $0.03 | $0.03 |
| 16 Jan 2026 | $0.03 | $0.00 | 0.00% | 133,989 | $0.03 | $0.03 | $0.03 |
| 12 Jan 2026 | $0.03 | $0.00 | 0.00% | 30,000 | $0.03 | $0.03 | $0.03 |
| 09 Jan 2026 | $0.03 | $0.00 | 0.00% | 42,936 | $0.03 | $0.03 | $0.03 |
| 05 Jan 2026 | $0.02 | $0.00 | 0.00% | 277,690 | $0.03 | $0.03 | $0.02 |
| 02 Jan 2026 | $0.03 | $0.00 | 0.00% | 9,843 | $0.03 | $0.03 | $0.03 |
| 29 Dec 2025 | $0.02 | $0.00 | 0.00% | 291 | $0.02 | $0.02 | $0.02 |
| 23 Dec 2025 | $0.02 | $0.00 | 0.00% | 65,772 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 21 Jul 2025 | Peter May | Issued | 217,392 | $5,000 |
Placement.
|
| 21 Jul 2025 | Peter May | Issued | 217,392 | $3,913 |
Issue of options.
|
| 21 Jul 2025 | Andrew Guthrie | Issued | 217,392 | $3,913 |
Issue of options.
|
| 21 Jul 2025 | Andrew Guthrie | Issued | 217,392 | $5,000 |
Placement.
|
| 21 Jul 2025 | Alex Ding | Issued | 21,739,130 | $499,999 |
Placement.
|
| 21 Jul 2025 | Alex Ding | Issued | 21,739,130 | $391,304 |
Issue of options.
|
| 21 Jul 2025 | Owen Grogan | Issued | 217,392 | $3,913 |
Issue of options.
|
| 21 Jul 2025 | Owen Grogan | Issued | 217,392 | $5,000 |
Placement.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Peter May | Research & DevelopmentExecutive Director | May 2015 |
Mr May career has included over 20 years of experience in the Australian and international crop protection and pest management markets with companies Orica and Crop Care (now part of Nufarm). In 2001, he founded Xavca Pty Ltd, providing marketing and consultancy services to mainly international clients including Syngenta and Sorex (now part of BASF).
|
| Mr Andrew Wallace Guthrie | Non-Executive Director | Apr 2021 |
Mr Guthrie spent 20 years working internationally with assignments in the United Kingdom, Switzerland, Hong Kong, Singapore, Thailand, Japan and China. He gained experience in diverse cultural environments that require leadership skills. He spent most of his senior leadership years with Syngenta in Asia, as Regional Director for Asia Pacific, before he was promoted to lead Syngenta's business in Europe, Africa and the Middle East. He is Chair of Risk Committee.
|
| Mr Alex Huong Soo Ding | Non-Executive DirectorNon-Executive Chairman | May 2023 |
Mr Ding has over 25 years of experience as a corporate lawyer. He was a partner at two leading Australian law firms and has experience in mergers and acquisitions, markets, and general corporate and governance law. He has advised many ASX, LSE and US listed companies, foreign government-controlled entities and private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy.
|
| Mr Christopher Mark Ramsey | Non-Executive Director | May 2023 |
Mr Ramsey has over 30 years of experience in the agricultural sector across business startup, development, marketing and agronomy. He has held leadership roles in Bayer, BASF and Nufarm/Crop Care among others, operating in both technical and managerial roles. He brings with him experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. He currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and RegenCo Natural Capital Specialists. He is member of Risk Committee.
|
| Mr Owen Timothy Grogan | Chief Executive OfficerManaging Director | Aug 2023 |
Mr Grogan brings more than 30 years of experience and expertise to Bio-Gene, with a record of delivering growth in the agtech, food and human health sectors. He has multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, he has held several executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, he led the commercial development of technologies to produce new types of healthier sugar.
|
| Mr Edmond Tern | Chief Financial OfficerCompany Secretary | Apr 2024 |
-
|
| Edmond Tern | Chief Financial OfficerCompany Secretary |
-
|
|
| Peter May | Executive Director - Research and Development |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Vana Belle Pty Ltd | 34,001,034 | 11.10% |
| Dr Choon Lee | 32,791,245 | 10.70% |
| Mark Chang | 21,109,174 | 6.90% |
| Alina Barlow | 18,995,859 | 6.20% |
| Citicorp Nominees | 15,166,491 | 5.00% |
| James Guest | 11,983,028 | 3.90% |
| T & L Ainsworth Investments | 6,683,185 | 2.20% |
| John Sommers | 5,224,260 | 1.70% |
| Kevin Rumble | 4,813,927 | 1.60% |
| David Massey | 4,476,259 | 1.50% |
| Alianda Oaks | 4,347,826 | 1.40% |
| Maclee Pty Ltd | 3,650,000 | 1.20% |
| Richard Jagger | 3,412,918 | 1.10% |
| Pl Moran | 3,310,000 | 1.10% |
| Arision Pty Limited | 2,955,265 | 1.00% |
| Bitola | 2,430,000 | 0.80% |
| Sm Investment | 2,407,626 | 0.80% |
| Grant Eshuys | 2,173,913 | 0.70% |
| Anthony Olding | 2,150,000 | 0.70% |
| Peter May | 2,059,597 | 0.70% |